Skip to main content

Genome Sequence and Assessment of Safety and Potential Probiotic Traits of Lactobacillus johnsonii CNCM I-4884

  • 2022-01-25
  • Microorganisms 10(2)
    • Anne-Sophie Boucard
    • I. Florent
    • B. Polack
    • P. Langella
    • L. Bermúdez-Humarán

Abstract

The probiotic strain Lactobacillus johnsonii CNCM I-4884 exhibits anti-Giardia activity in vitro and in vivo in a murine model of giardiasis. The aim of this study was the identification and characterization of the probiotic potential of L. johnsonii CNCM I-4884, as well as its safety assessment. This strain was originally classified as Lactobacillus gasseri based on 16S gene sequence analysis. Whole genome sequencing led to a reclassification as L. johnsonii. A genome-wide search for biosynthetic pathways revealed a high degree of auxotrophy, balanced by large transport and catabolic systems. The strain also exhibits tolerance to low pH and bile salts and shows strong bile salt hydrolase (BSH) activity. Sequencing results revealed the absence of antimicrobial resistance genes and other virulence factors. Phenotypic tests confirm that the strain is susceptible to a panel of 8 antibiotics of both human and animal relevance. Altogether, the in silico and in vitro results confirm that L. johnsonii CNCM I-4884 is well adapted to the gastrointestinal environment and could be safely used in probiotic formulations.

Keywords: Lactobacillus johnsonii; genome sequencing; identification; probiotic; safety.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus johnsonii LJ09Reduced Giardia intestinalis InfectionBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.